natgillin/translations-raw huggingface dataset:
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01 % i &lt; 0,1 %) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su zabilježeni (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su rijetko zabilježeni (≥ 0.01% i &lt; 0,01 %) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su rijetko zabilježeni (≥ 0.01% i &lt; 0,01 %) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and &lt; 0.1%) when oral olanzapine is stopped abruptly.
Kod naglog prestanka peroralne primjene olanzapina rijetko su prijavljeni (≥ 0,01% i &lt; 0,1%) akutni simptomi poput znojenja, nesanice, tremora, anksioznosti, mučnine ili povraćanja.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely rarely ( ≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01 % i &lt; 0,1 %) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely rarely (≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01 % i &lt; 0,1 %) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su zabilježeni (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ≥0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported very rarely (≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
ADCS-CGIC scores &lt; 4 indicate improvement.
Rezultati na ADCS-CGIC-u od &lt; 4 upućuju na poboljšanje.
Additional adverse drug reactions identified associated with the use of the combination therapy (BR-CAP) were hepatitis B infection ( &lt; 1%) and myocardial ischaemia (1.3%).
Dodatne identificirane nuspojave povezane s primjenom kombiniranog liječenja (BR-CAP) bile su infekcija hepatitisom B ( &lt; 1%) i ishemija miokarda (1,3%).
Additional adverse drug reactions identified associated with the use of the combination therapy (BzmbR-CAP) were hepatitis B infection ( &lt; 1%) and myocardial ischaemia (1.3%).
Dodatne identificirane nuspojave povezane s primjenom kombiniranog liječenja (BzmbR-CAP) bile su infekcija hepatitisom B ( &lt; 1 %) i ishemija miokarda (1,3 %).
Additional adverse drug reactions identified associated with the use of the combination therapy (BzR-CAP) were hepatitis B infection ( &lt; 1%) and myocardial ischaemia (1.3%).
Dodatne identificirane nuspojave povezane s primjenom kombiniranog liječenja (BzR-CAP) bile su infekcija hepatitisom B ( &lt; 1%) i ishemija miokarda (1,3%).
Additional adverse drug reactions identified associated with the use of the combination therapy (VcR-CAP) were hepatitis B infection ( &lt; 1%) and myocardial ischaemia (1.3%).
Dodatne identificirane nuspojave povezane s primjenom kombiniranog liječenja (VcR-CAP) bile su infekcija hepatitisom B ( &lt; 1%) i ishemija miokarda (1,3%).
Additional adverse experiences reported regardless of causal relationship to medication that occurred more frequently in patients treated with sitagliptin (not reaching the 5 % level, but occurring with an incidence of &gt; 0.5 % higher with sitagliptin than that in the control group) included osteoarthritis and pain in extremity.
Dodatne nuspojave prijavljene bez obzira na uzročno-posljedičnu povezanost s liječenjem koje su se pojavile češće u bolesnika liječenih sitagliptinom (nisu dostigle razinu od 5%, ali su se pojavljivale s incidencijom &gt; 0,5% višom sa sitagliptinom od one koju je imala kontrolna skupina) uključivale su osteoartritis i bol u ekstremitetima.
Additional adverse reactions not listed in Table 2 have been reported in patients who received other doses (either &lt; or &gt; 3 mg/kg) of ipilimumab in clinical trials of melanoma.
Dodatne nuspojave koje nisu navedene u tablici 2 zabilježene su u bolesnika koji su primili drugačije doze ( &lt; ili &gt; 3 mg/kg) ipilimumaba u kliničkim ispitivanjima liječenja melanoma.
Additional adverse reactions observed when used outside of the recommended dose and indication (i.e. used in CTCL at an initial dose &gt; 300mg/m2/day or in non-CTCL cancer indications):
Dodatne nuspojave opažene kod primjene doza izvan preporučenih razina i indikacije (tj. primijenjenih kod CTCL-a u početnoj dozi od &gt; 300mg/m2 na dan ili onkoloških indikacija bez CTCL-a):
Additional analyses suggest that the surgical procedure type did not influence the trends in efficacy endpoints and the efficacy of IONSYS was similar across the range of body mass indices studied ( &lt; 25 to &gt; 40 kg/m2 Body Mass Index).
Dodatne analize upućuju na to da vrsta kirurškog zahvata nije utjecala na trendove u mjerama ishoda djelotvornosti, a djelotvornost sustava IONSYS bila je slična u ispitanom rasponu indeksa tjelesne mase (indeks tjelesne mase od &lt; 25 do ≥40 kg/m2).
Additional educational materials for healthcare professionals are available on the following URL: [URL to be included] &lt; and the &lt; Member State &gt; website &gt; .
Dodatni edukacijski materijali za zdravstvene djelatnike dostupni su na sljedećem URL: [URL će biti upisan] &lt; i &lt; zemlja članica &gt; web-stranica &gt; .
Additional risk minimisation measures &gt;
Dodatne mjere minimizacije rizika
Additional side effects in children aged 2 months to &lt; 3 years
Dodatne nuspojave u djece u dobi od 2 mjeseca do &lt; 3 godine
Additionally, dose adjustment of zidovudine may be required if severe anaemia or myelosuppression occurs during treatment with Trizivir, or in patients with pre-existing bone marrow compromise e.g. haemoglobin &lt; 9 g/dl (5.59 mmol/l) or neutrophil count &lt; 1.0 x 109/l (see section 4.2).
Potreba za prilagođavanjem doze zidovudina se može javiti u slučaju pojave teške anemije ili mijelosupresije u bolesnika liječenih lijekom Trizivir ili u bolesnika s prethodnom bolešću koštane srži, tj. s vrijednošću hemoglobina &lt; 9 g/dl (5,59 mmol/l) ili brojem neutrofila &lt; 1,0 x 109/l (vidjeti dio 4.2).
Additionally, GMTs for measles, mumps, and rubella were similar to those following a second dose of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. given concomitantly with placebo (for safety information, see section 4.8).
Osim toga, geometrijski srednji titar za morbile, parotitis i rubelu bio je sličan onom nakon druge doze cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. primijenjenog istodobno s placebom (za informacije o sigurnosti, vidjeti dio 4.8).
Additionally, if after 6 hours the heart rate is &lt; 45 bpm or if the ECG at 6 hours after the first dose shows second degree or higher AV block, or if it shows a QTc interval ≥500 msec, monitoring should be extended at least for overnight and until the findings have resolved.
Uz to, ako je nakon 6 sati srčana frekvencija &lt; 45 otkucaja u min ili ako EKG 6 sati nakon prve doze pokazuje AV blok drugog ili višeg stupnja, ili ako pokazuje QTc interval ≥500 msek, praćenje treba produžiti barem preko noći i do povlačenja simptoma.
Additionally, if after 6 hours, the heart rate is &lt; 45 bpm, or the ECG shows new onset second degree or higher grade AV block or a QTc interval ≥500 msec, extended monitoring (at least overnight monitoring), should be performed, and until the findings have resolved.
Osim toga, ako je nakon 6 sati srčana frekvencija &lt; 45 otkucaja u minuti ili ako EKG pokazuje novi nastup AV bloka drugog ili višeg stupnja ili QTc interval ≥500 msek, treba obaviti produljeno praćenje (barem preko noći) te nastaviti dok se nalaz ne popravi.
Additionally, other adverse events have been reported with post- marketing use of ProQuad and/or in clinical studies and post-marketing use of either the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc., the monovalent component vaccines of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc., or Varicella Vaccine live (Oka/Merck).
Nadalje, drugi štetni događaji prijavljeni su prilikom primjene cjepiva ProQuad nakon njegova stavljanja u promet i/ili u kliničkim ispitivanjima i prilikom primjene cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc., monovalentnih cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. ili živog cjepiva protiv varičele (Oka/Merck) nakon njihova stavljanja u promet.
Additionally, other adverse reactions reported with post-marketing use of M-M-RVAXPRO and/or in clinical studies and post-marketing use of previous formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured by Merck &amp; Co., Inc. without regard to causality or frequency are available and are summarised in section b (frequency not known).
Osim toga, druge nuspojave prijavljene nakon stavljanja cjepiva M-M-RVAXPRO u promet i/ili tijekom kliničkih ispitivanja i nakon stavljanja u promet prethodnih monovalentnih i kombiniranih cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc., bez obzira na njihovu uzročno-posljedičnu povezanost ili učestalost navedene su u dijelu b (učestalost nepoznato).
Additionally, paediatric patients &lt; 1 year of age experienced about two times more often an increase in ALT, AST and AP than older paediatric patients (see section 4.4).
Osim toga, povišenje ALT, AST i AP se javljalo oko dva puta češće u pedijatrijskih bolesnika u dobi do 1 godine nego u starijih pedijatrijskih bolesnika (vidjeti dio 4.4).
Adefovir dipivoxil is not recommended in patients with a creatinine clearance of &lt; 30 ml/min or on dialysis.
Adefovirdipivoksil ne preporučuje se u pacijenata s klirensom kreatinina &lt; 30 ml/min ili onih na dijalizi.
Adefovir dipivoxil is not recommended in patients with creatinine clearance of &lt; 30 ml/min or in patients on dialysis (see section 4.2 and 4.4).
Adefovirdipivoksil ne preporučuje se za liječenje pacijenata s klirensom kreatinina &lt; 30 ml/min ili u pacijenata na dijalizi (vidjeti dijelove 4.2 i 4.4).
Adjusted mean change from baseline was 3.8 for etanercept treated (n = 95) versus 0.8 for placebo treated (n = 105) patients (p &lt; 0.001).
Prilagođena srednja promjena u odnosu na početni rezultat iznosila je 3,8 u bolesnika liječenih etanerceptom (n = 95) naspram 0,8 u bolesnika liječenih placebom (n = 105) (p &lt; 0,001).
adjusted rate b p &lt; 0.001, Humira vs. placebo
istraživačkom centru b p &lt; 0,001, Humira naspram placeba
Adjustment of the starting Abraxane dose is not required for patients with mild to moderate renal impairment (estimated creatinine clearance ≥30 to &lt; 90 ml/min).
Prilagodba početne doze lijeka Abraxane nije potrebna u bolesnika s blagim do umjerenim oštećenjem bubrežne funkcije (procijenjeni klirens kreatinina od ≥ 30 do &lt; 90 ml/min).
Adjustments of the daily dose of tenofovir disoproxil (as fumarate) 33 mg/g granules are recommended in patients with moderate (creatinine clearance 30-49 ml/min) or severe (creatinine clearance &lt; 30 ml/min) renal impairment based on modelling of single-dose pharmacokinetic data in HIV negative and non-HBV infected subjects with varying degrees of renal impairment, including end-stage renal disease requiring haemodialysis.
Prilagođavanja dnevnih doza tenofovirdizoproksila (u obliku tenofovirdizoproksilfumarata) 33 mg/g granula preporučuju se u pacijenata s umjerenim (klirens kreatinina 30-49 ml/min) ili teškim (klirens kreatinina &lt; 30 ml/min) oštećenjem funkcije bubrega na temelju modela podataka o farmakokinetici jednokratnih doza u HIV negativnih ispitanika koji nisu bili zaraženi virusom hepatitisa B, a imali su oštećenje funkcije bubrega različitih stupnjeva, uključujući i bubrežnu bolest u završnoj fazi za koju je bila potrebna hemodijaliza.
Administer IMBRUVICA to patients with severe renal impairment ( &lt; 30 mL/min creatinine clearance) only if the benefit outweighs the risk and monitor patients closely for signs of toxicity.
Bolesnicima s teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min) lijek IMBRUVICA smije se primijeniti samo ako korist nadilazi rizik te je potrebno pažljivo pratiti bolesnike zbog moguće pojave znakova toksičnosti.
Administration of capecitabine should be interrupted if treatment- related elevations in bilirubin of &gt; 3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of &gt; 2.5 x ULN occur.
Primjenu kapecitabina treba prekinuti ako uzimanje lijeka izazove povećanje vrijednosti bilirubina &gt; 3,0 x iznad gornje granice normale (GGN) ili jetrenih aminotransferaza (ALT, AST) &gt; 2,5 x iznad GGN.
Administration of capecitabine should be interrupted if treatment- related elevations in bilirubin of &gt; 3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of &gt; 2.5 x ULN occur.
Primjenu kapecitabina treba prekinuti ako uzimanje lijeka izazove povećanje vrijednosti bilirubina &gt; 3,0 x iznad gornje granice normale ili jetrenih aminotransferaza (ALT, AST) &gt; 2,5 x iznad gornje granice normale.
Administration of capecitabine should be interrupted if treatment-related elevations in bilirubin of &gt; 3.0 x ULN or treatment- related elevations in hepatic aminotransferases (ALT, AST) of &gt; 2.5 x ULN occur.
Primjenu kapecitabina treba prekinuti ako uzimanje lijeka izazove povećanje vrijednosti bilirubina &gt; 3,0 x iznad gornje granice normale ili jetrenih aminotransferaza (ALT, AST) &gt; 2,5 x iznad gornje granice normale.
Administration of capecitabine should be interrupted if treatment-related elevations in bilirubin of &gt; 3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of &gt; 2.5 x ULN occur.
Primjenu kapecitabina treba prekinuti ako uzimanje lijeka izazove povećanje vrijednosti bilirubina &gt; 3,0 x iznad gornje granice normale ili jetrenih aminotransferaza (ALT, AST) &gt; 2,5 x iznad gornje granice normale.
Administration of hydroxocobalamin was generally associated with a normalisation of blood pressure (systolic blood pressure &gt; 90 mmHg) in 17 of 21 patients (81%) who had low blood pressure (systolic blood pressure &gt; 0 and ≤ 90 mmHg) after exposure to cyanide.
Primjena hidroksokobalamina bila je općenito povezana s normalizacijom krvnog tlaka (sistolički krvni tlak &gt; 90 mmHg) kod 17 od 21 bolesnika (81%) koji su imali nizak krvni tlak (sistolički krvni tlak &gt; 0 i ≤ 90 mmHg) nakon izlaganja cijanidu.
Administration of Viread 33 mg/g granules to provide a reduced daily dose of tenofovir disoproxil fumarate is recommended for adult patients with creatinine clearance &lt; 50 ml/min, including haemodialysis patients.
Primjena Viread 33 mg/g granula za omogućavanje snižene dnevne doze tenofovirdizoproksilfumarata preporučuje se za odrasle pacijente s klirensom kreatinina &lt; 50 ml/min, uključujući pacijente na hemodijalizi.
Adolescents (12 &lt; 18 years)
Adolescenti (12 – &lt; 18 godina)
Adolescents (9- &lt; 18 years)
Adolescenti (9- &lt; 18 godina)
Adolescents 12 to &lt; 18
Adolescenti 12 do &lt; 18
Adolescents aged 12 to &lt; 18 years: 50 mg of tigecycline every 12 hours for 5 to 14 days.
Adolescenti u dobi od 12 do &lt; 18 godina: 50 mg tigeciklina svakih 12 sati tijekom 5 do 14 dana.
Adolescents weighing &lt; 51 kg: the maximum recommended daily dose of INVEGA is 6 mg.
Adolescenti težine &lt; 51 kg: maksimalna preporučena dnevna doza lijeka INVEGA je 6 mg.
Adolescents(9- &lt; 18 years)
Adolescenti (9- &lt; 18 godina)
ADRs are listed in Table 3 below by MedDRA system organ class and by frequency: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to
Nuspojave su navedene u Tablici 3 prema MedDRA-klasifikaciji organskih sustava i učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do
Adult ( &gt; 18 years)
Odrasli ( &gt; 18 godina)
Adult and adolescent (≥ 12 to &lt; 18 years old and weighing ≥ 30 kg) patients who had a FEV1 percent predicted between 25% and 85% were enrolled.
U ispitivanje su bili uključeni odrasli bolesnici i adolescenti (u dobi od ≥ 12 do &lt; 18 godina i tjelesne težine ≥ 30 kg) kod kojih je postotak FEV1 bio između 25% i 85% predviđene vrijednosti.
Adult patients with severe renal impairment (creatinine clearance of &lt; 30 mL/minute) and patients with End Stage Renal Disease (ESRD) or on haemodialysis should be administered Ribavirin Mylan 200 mg/day.
Odrasli bolesnici s teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min) i bolesnici sa završnim stadijem oštećenja bubrega (ESRD) ili bolesnici na hemodijalizi trebaju primjenjivati Ribavirin Mylan u dozi od 200 mg/dan.
Adult population aged 65 years or older with AML with &gt; 30% marrow blasts
Odrasla populacija u dobi od 65 ili više godina s AML-om s &gt; 30 % blasta u koštanoj srži
Adults ( &gt; 21 and &lt; 65 years old)
Odrasli (u dobi &gt; 21 i &lt; 65 godina)
Adults &gt; 21 years
Odrasli u dobi ˃21 godine
Adults &gt; 30 years
Odrasli &gt; 30 godina
Adults and adolescents aged from 12 to &lt; 18 years with bodyweight ≥ 33 kg: see Table 1.
Odrasli i adolescenti u dobi od navršenih 12 do &lt; 18 godina čija je tjelesna težina ≥33 kg: vidjeti Tablicu 1.
Adults and children &gt; 6 year
Odrasli i djeca &gt; 6 godina
Adults and elderly ( &gt; 65 years)
Odrasli i starije osobe ( &gt; 65 godina)
Adults, adolescents or children ( &gt; 40 kg) who are able to swallow capsules may receive appropriate doses of Tamiflu capsules.
Odrasli, adolescenti ili djeca ( &gt; 40 kg) koji mogu progutati kapsulu mogu primiti odgovarajuće doze Tamiflu kapsula.
Adverse reaction frequencies are defined as: very common (≥1/10), common (≥1/100, &lt; 1/10), uncommon (≥1/1,000, &lt; 1/100), rare (≥1/10,000, &lt; 1/1,000) or very rare ( &lt; 1/10000).
Učestalosti nuspojava određene su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100, &lt; 1/10), manje često (≥ 1/1000, &lt; 1/100), rijetko (≥ 1/10 000, &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
Adverse reaction frequencies: Very common (≥1/10), Common (≥1/100 to &lt; 1/10), not known (cannot be estimated from the available data).
Učestalosti nuspojava: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), nepoznato (ne može se utvrditi iz dostupnih podataka).
Adverse reactions are categorized according to the following frequencies: very common ( 1/10); common ( 1/100 to  1/10); uncommon ( 1/1,000 to  1/100); rare ( 1/10,000 to  1/1,000); not known (cannot be estimated from the available data).
Nuspojave su kategorizirane prema sljedećoj učestalosti: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nije poznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are listed below in Table 1 by system organ class and frequency (frequencies are defined as: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene niže u tablici 1 prema klasifikaciji organskih sustava i učestalosti (učestalosti su definirane kao: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are listed below using the following convention : very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Nuspojave su navedene niže i prema učestalosti razvrstane su na sljedeći način: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
Adverse reactions are listed below using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su niže navedene prema sljedećoj učestalosti: vrlo često (1/10); često (1/100 i &lt; 1/10); manje često (1/1000 i &lt; 1/100) ; rijetko (1/10 000 i &lt; 1/1000) ; vrlo rijetko ( &lt; 1/10 000) ; nepoznato (ne može se procijeniti iz dostupnih podataka).